Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Rigel (RIGL), Arcturus Therapeutics (ARCT) and Intellia Therapeutics (NTLA)

Tipranks - Tipranks - Thu Mar 5, 5:10AM CST

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Rigel (RIGL – Research Report), Arcturus Therapeutics (ARCT – Research Report) and Intellia Therapeutics (NTLA – Research Report) with bullish sentiments.

Claim 70% Off TipRanks Premium

Rigel (RIGL)

Citi analyst Yigal Nochomovitz maintained a Buy rating on Rigel today and set a price target of $71.00. The company’s shares closed last Tuesday at $33.02.

According to TipRanks.com, Nochomovitz is a 3-star analyst with an average return of 3.0% and a 39.1% success rate. Nochomovitz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Lexicon Pharmaceuticals, and Arvinas Holding Company. ;'>

Currently, the analyst consensus on Rigel is a Moderate Buy with an average price target of $52.00, a 52.4% upside from current levels. In a report released today, TipRanks – PerPlexity also reiterated a Buy rating on the stock with a $39.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Arcturus Therapeutics (ARCT)

William Blair analyst Myles Minter reiterated a Buy rating on Arcturus Therapeutics today and set a price target of $7.91. The company’s shares closed last Tuesday at $7.91.

According to TipRanks.com, Minter is a 5-star analyst with an average return of 32.0% and a 60.9% success rate. Minter covers the Healthcare sector, focusing on stocks such as CAMP4 Therapeutics Corporation, Neumora Therapeutics, Inc., and Entrada Therapeutics Inc. ;'>

Arcturus Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $16.00, representing a 100.3% upside. In a report released yesterday, BTIG also maintained a Buy rating on the stock with a $23.00 price target.

Intellia Therapeutics (NTLA)

JonesTrading analyst Debanjana Chatterjee upgraded Intellia Therapeutics to Buy today and set a price target of $29.00. The company’s shares closed last Tuesday at $13.61.

According to TipRanks.com, Chatterjee is a 5-star analyst with an average return of 45.1% and a 66.7% success rate. Chatterjee covers the Healthcare sector, focusing on stocks such as Contineum Therapeutics, Inc. Class A, Sagimet Biosciences, Inc. Class A, and Sionna Therapeutics, Inc. ;'>

Intellia Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $21.17, which is a 43.1% upside from current levels. In a report issued on March 2, William Blair also upgraded the stock to Buy.

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).